Compare Bank of Montreal (BMO) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Montreal vs DexCom, Inc. — how do they compare? Bank of Montreal trades at $181.96 (market cap $125.53B), while DexCom, Inc. trades at $76.3 (market cap $28.60B). The key difference: Bank of Montreal is far larger — about 4.4× DexCom, Inc.'s market cap, and Bank of Montreal pays a 2.74% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| BMO | DXCM | |
|---|---|---|
Market Cap | $125.53B | $28.60B |
Sector | Financials | Health |
52-Week High | $180.86 | $89.53 |
52-Week Low | $110.44 | $54.84 |
Dividend Yield | 2.74% | — |
Enterprise Value | — | $27.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BMO trades at $178.69, down 0.15% today, with a bullish technical signal supported by moving averages and key resistance at $180. The company reported strong Q1 2026 earnings of $2.68 per share, beating estimates, and maintains a solid net income margin of 25.92%. Recent acquisitions and dividend increases highlight strategic growth, while analyst sentiment is balanced with 44% buy ratings.
Outlook remains positive driven by consistent earnings beats and expansion in metals & mining banking. Risks include valuation above historical norms with a P/E of 19.48 and exposure to interest rate sensitivity. The stock offers a compelling dividend yield but faces macroeconomic headwinds that could pressure future performance.
DXCM trades at $76.35, up 1.85% today, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 17.93% net income margin and consistent earnings beats. Recent regulatory approvals for G7 15-day CGM in Canada and pediatric clearance for Stelo OTC system highlight growth catalysts. Revenue growth accelerated to $4.66 billion in 2025, up from $4.0 billion in 2024.
DXCM presents a compelling growth story with expanding CGM market access and strong analyst support (80% buy ratings). Key risks include GLP-1 adoption impact on core market and execution of Type 2 non-insulin patient expansion. The stock trades at a premium valuation (P/E 32.76) but offers upside to consensus target of $83.78. Near-term focus on Q2 2026 earnings release July 30.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of Montreal
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
